HER2 Support Group Forums - View Single Post - for thoseneeding dual her2 therapy whose liver is so involved it is not able to adeq-

Lani · 06-07-2014, 04:52 PM

ately function, suggestion to use carboplatin as a poosible substitute with H+P (case study report):

BMJ Case Rep. 2014 Jun 4;2014. pii: bcr2013203400. doi: 10.1136/bcr-2013-203400.
Metastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin.
Macias MN, Shin DS, Ledezma B, Sadeghi S.
Author information

Abstract
A 30-year-old woman presented to an outside hospital with pain in the right upper abdomen. Imaging revealed over 100 liver lesions, the largest measuring 74 mm×71 mm, and multiple lytic bone lesions. An outpatient liver biopsy showed a poorly differentiated adenocarcinoma favouring a breast primary. The tumour was oestrogen and progesterone receptor negative, but human epidermal growth factor 2 (HER2/neu) amplified. In her second clinic visit she had decompensated liver failure manifested by new-onset ascites and jaundice. Initially, the chemotherapy plan was for docetaxel, pertuzumab and trastuzumab, but given her severe liver dysfunction we used a combination of carboplatin, pertuzumab and trastuzumab as an inpatient. She was hospitalised for 14 days and eventually discharged with a marked improvement of her symptoms and liver tests. She subsequently completed five outpatient chemotherapy cycles. We showed that carboplatin is a possible alternative to docetaxel when severe liver dysfunction precludes docetaxel's use in combination with pertuzumab and trastuzumab.
2014 BMJ Publishing Group Ltd.
PMID: 24899001 [PubMed - in process]

06-07-2014, 04:52 PM	#1
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	for thoseneeding dual her2 therapy whose liver is so involved it is not able to adeq- ately function, suggestion to use carboplatin as a poosible substitute with H+P (case study report): BMJ Case Rep. 2014 Jun 4;2014. pii: bcr2013203400. doi: 10.1136/bcr-2013-203400. Metastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin. Macias MN, Shin DS, Ledezma B, Sadeghi S. Author information Abstract A 30-year-old woman presented to an outside hospital with pain in the right upper abdomen. Imaging revealed over 100 liver lesions, the largest measuring 74 mm×71 mm, and multiple lytic bone lesions. An outpatient liver biopsy showed a poorly differentiated adenocarcinoma favouring a breast primary. The tumour was oestrogen and progesterone receptor negative, but human epidermal growth factor 2 (HER2/neu) amplified. In her second clinic visit she had decompensated liver failure manifested by new-onset ascites and jaundice. Initially, the chemotherapy plan was for docetaxel, pertuzumab and trastuzumab, but given her severe liver dysfunction we used a combination of carboplatin, pertuzumab and trastuzumab as an inpatient. She was hospitalised for 14 days and eventually discharged with a marked improvement of her symptoms and liver tests. She subsequently completed five outpatient chemotherapy cycles. We showed that carboplatin is a possible alternative to docetaxel when severe liver dysfunction precludes docetaxel's use in combination with pertuzumab and trastuzumab. 2014 BMJ Publishing Group Ltd. PMID: 24899001 [PubMed - in process]